ROCKAWAY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place virtually on April 10, 2025.
Dan Goldberger, CEO and Joshua Lev, Chief Financial Officer, will host a group presentation at 2:15 p.m. ET and participate in one-on-one meetings throughout the day.
DATE: April 10, 2025
TIME: 2:15 p.m. ET
WEBCAST: electroCore Group Presentation
A live audio webcast and replay of the presentation will be available using the above dedicated link. Investors attending the conference who are interested in scheduling a meeting with management can do so by contacting their Needham representative, or by emailing FNK IR at This email address is being protected from spambots. You need JavaScript enabled to view it. for more information.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Contact
ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.27 |
| Daily Change: | -0.12 -1.62 |
| Daily Volume: | 43,298 |
| Market Cap: | US$53.940M |
March 12, 2025 February 27, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
